154
Participants
Start Date
January 18, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2028
mitoxantrone liposome, Ara-Cytarabine and azacitidine
Mitoxantrone hydrochloride liposome 24 mg/m2, IV every 4 weeks, day 1; Ara-Cytarabine 100 mg/m2, IV every 12 h, days 1-7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7
Daunorubicin,Ara-Cytarabine, azacitidine
Daunorubicin 60 mg/m2, intravenously, once daily, days 1 to 3; Ara-Cytarabine 100 mg/m2, IV drip, every 12h, days 1 to 7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7;
NOT_YET_RECRUITING
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Wuxi
RECRUITING
Zhongnan Hospital of Wuhan University, Wuhan
NOT_YET_RECRUITING
The Central Hospital of Xiaogan, Xiaogan
NOT_YET_RECRUITING
The First People's Hospital of Jingzhou, Jingzhou
NOT_YET_RECRUITING
Jingzhou Central Hospital, Jingzhou
NOT_YET_RECRUITING
Xianning Central Hospital, Xianning
NOT_YET_RECRUITING
The Central Hospital of Huanggang, Huanggang
NOT_YET_RECRUITING
Shiyan Taihe Hospital, Shiyan
NOT_YET_RECRUITING
Yichang Central Hospital, Yichang
NOT_YET_RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
NOT_YET_RECRUITING
Shanxi Cancer Hospital, Taiyuan
Ruijin Hospital
OTHER
Shanxi Province Cancer Hospital
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Jingzhou Central Hospital
OTHER
Yichang Central People's Hospital
OTHER
Taihe Hospital
OTHER
Central Hospital of Xiaogan
OTHER
Xianning Central Hospital
OTHER
The First People's Hospital of Jingzhou
OTHER
Zhongnan Hospital
OTHER